Key points from article :
This Series A was led by Leaps by Bayer, 8VC and Humboldt Fund.
"... what drew them to Cellino was our ability to automate these complex processes” - Nabiha Saklayen, co-founder and CEO.
Cellino’s total funding is $96 million to date.
Cellino is looking to automate the process we use to create human induced pluripotent stem cells (iPSCs).
Large Phase III trials will need methods to make many of these cells in a reliable way.
Cellino uses a laser-based cell-editing system to eliminate cells that aren’t up to the task of regenerating tissues.
The dream is to build a truly autonomous human cell foundry by 2025.
Cellino collaborating with Kapil Bharti at the National Eye Institute to transplant personalized iPSCs into patient retinas, with the hopes of treating age-related macular degeneration.
Investment will be spent in two main areas:
- expand the machine learning capacity of the platform
- comparing its stem cells to those derived from existing, but slower techniques
